Abstract | Patients with pancreatic cancer normally present with advanced disease that is lethal and notoriously difficult to treat. survival has not improved dramatically despite routine use of chemotherapy and radiotherapy; this situation signifies an urgent need for novel therapeutic approaches. Over the past decade, a large number of studies have been published that aimed to target the molecular abnormalities implicated in pancreatic tumor growth, invasion, metastasis, angiogenesis and resistance to apoptosis. This research is of particular importance, as data suggest that a large number of genetic alterations affect only a few major signaling pathways and processes involved in pancreatic tumorigenesis. Although laboratory results of targeted therapies have been impressive, until now only erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has demonstrated modest survival benefit in combination with gemcitabine in a phase iii clinical trial. whilst the failures of targeted therapies in the clinical setting are discouraging, lessons have been learnt and new therapeutic targets that hold promise for the future management of the disease are continuously emerging. This review describes some of the important developments and targeted agents for pancreatic cancer that have been tested in clinical trials.
Introduction
Pancreatic cancer remains an important health problem. Known risk factors for the disease include cigarette smoking, chronic and hereditary pancreatitis, lateonset diabetes mellitus and familial cancer syndromes. Pancreatic cancer is one of the most difficult conditions to treat, although it only accounts for 3% of all cancers; 5-year survival is about 5% in patients with the disease and this figure has remained largely unchanged over the past 25 years. 1 The majority of patients present with locally advanced or metastatic disease, and such indivi duals have a median survival of 6-10 months and 3-6 months, respectively.
2 Although 10-15% of patients have potentially resectable tumors, many experience recurrence of disease following surgery. Gemcitabine is the standard chemotherapeutic drug for patients with advanced pancreatic cancer, after a phase III trial in 1997 demonstrated a modest survival advantage of this agent over 5-fluorouracil (median survival 5.65 months versus 4.41 months, P = 0.0025), and improved allevia tion of disease-related symptoms. 3 Given the limited effect of conventional therapies, however, a desperate need for improved diagnostic and treatment modalities remains. Considerable resources have been channeled to the development of novel therapies that target the mol ecular aberrations of the disease (Table 1) . These targeted therapies are designed to disable the cell ular pathways that are essential for cancer to survive. Targeted therapies could also be used in a multimodal treatment regimen in combination with standard radiotherapy and chemotherapy to improve outcomes and overcome drug resistance. In 2008, detailed, global, genomic analyses found that a large number of genetic alterations (an average of 63) affect only a core set of 12 signaling pathways and processes that are genetically altered in 67-100% of cases of pancreatic cancer. 4 These data suggest that treatments for pancreatic cancer should target these complex and overlapping signaling pathways, rather than just the products of a single gene ( Figure 1 ). This Review describes some of the important developments in therapies for pancreatic cancer that have been tested both in the laboratory and, most importantly, in subsequent clinical trials.
reviews GTPase function, which causes KRas to be locked in the GTP-bound 'on' state. This malfunction triggers a variety of cellular processes, including transcription, translation, cell-cycle progression, enhanced cell survival and motility. oncogenic KRAS is involved in the initiation or early phase of pancreatic tumorigenesis.
A peptide vaccine that aims to stimulate immunity against cancer cells with mutant Ras proteins has been tested as an adjuvant treatment in patients with pancreatic cancer. 6 An extension to this research investi gated the effects of combination therapy with mutant Ras peptide plus granulocyte-macrophage colony-stimulating factor 7 or interleukin (Il)-2. 8 outcomes seemed to be favorable in these phase I-II trials, albeit only in individuals who mounted an immune response (about half of the patients).
For Ras to function, it must undergo post-translational modification so that it can attach to the cell membrane. one essential step involves the addition of a 15-carbon isoprenoid chain, mediated by farnesyltransferase. The therapeutic use of tipifarnib, a farnesyltransferase inhibitor (FTI), in combination with gemcitabine was disappointing in a phase III trial (Table 2) . 9 This finding could be partly explained by the fact that KRas can be alternatively prenylated by the addition of a 20-carbon isoprenoid moiety mediated by the enzyme geranylgeranyltransferase. Moreover, FTIs work largely by inhibi tion of the cell cycle, but gemcitabine needs cellcycle progression to be effective. To this end, a dual inhibitor of farnesyltransferase and geranylgeranyltransferase (l-778123) was tested in a phase I trial in combina tion with radiotherapy for locally advanced pancreatic cancer. 10 Inhibition of farnesylation and sensi tivity to radiotherapy was demonstrated in a patient-derived cell line. Further development of this drug was, nevertheless, halted owing to adverse cardiac effects. other compounds that are in early phases of clinical testing after yielding promising laboratory results include romidepsin, a histone deacetylase inhibitor that inhibits Ras-mediated signal transduction and thus causes cell-cycle arrest, 11 and farnesylthiosalicyclic acid (salirasib), which disrupts Ras from its membranebinding site. 12 These compounds seem to have clinical activity in combination with gemcitabine and further studies are warranted.
other strategies that target the Ras signaling pathway include the use of RnA-directed gene-silencing strategies, such as antisense therapy and RnA interference. Antisense therapy involves the use of oligonucleotides that have sequences complementary to a specific target messenger RnA (mRnA), which, therefore, block its translation to protein. In a phase II trial of patients with locally advanced and metastatic pancreatic cancers, the antisense inhibitor of another member of the Ras family (HRas), IsIs 2503, showed a response rate of 10.4% and a median survival of 6.6 months in combination with gemcitabine. 13 However, initial enthusiasm for this approach is diminishing following the failures of antisense inhibitors, such as IsIs 2503 and oblimersen in lung cancer and melanoma, respectively. An alternative method is RnA interference, which involves the manufacture of small interfering RnAs (siRnAs) that are specific for a particular target mRnA. These siRnAs bind to a complex of several proteins, including endoribonucleases, which is then termed the RnA-induced silencing complex. This complex identifies complementary mRnA and effects its cleavage or translational block. This technology is highly specific but has yet to 14, 15 MAP2K, the principal downstream component of Ras signaling, has also been the subject of targeted inhibition. In a phase II trial, the inhibitor CI-1040 (PD184532) did not demon strate enough antitumor activity to justify further development. 16 nevertheless, combined inhibition of MAP2K and other kinases (such as EGFR) has been effective in pre clinical studies, which suggests that this approach might still have a role in therapy for pancreatic cancer.
17,18
The epidermal growth factor receptor pathway EGFR is a transmembrane receptor tyrosine kinase of the ErbB family. upon binding to its ligands, homodimerization or heterodimerization with other members of the ErbB family occurs, which leads to phosphorylation of tyrosine residues in its intracellular domain. This process recruits intracellular proteins that cause downstream signaling events through MAPK, PI3K-AKT, and the sTAT family of proteins ( Figure 2 ). sTAT proteins have roles in cell proliferation, survival, motility, invasion and adhesion. Mechanisms that lead to inappropriate activation of EGFR include receptor overexpression, activating mutations, overexpression of receptor ligands, and/or loss of their negative regulatory pathways. overexpression of EGFR and its ligands EGF and TGF-α are frequently observed in pancreatic cancer. 19, 20 In a phase III trial in combination with gemcitabine, erlotinib, an orally active small molecule that binds to the ATP-binding site of EGFR, has demonstrated a small but significant increase in the survival of patients with advanced pancreatic cancer ( Table 2) . 21 In 2005, erlotinib was the first targeted therapy approved by the FDA for pancreatic cancer. However, its clinical relevance has been criticized and its cost-effectiveness has been questioned. 22 other EGFR tyrosine kinase inhibitors that have been tested in early-phase clinical trials include gefitinib [23] [24] [25] and lapatinib. 26, 27 Although EGFR inhibitors have shown promising results, inhibition of EGFR with the monoclonal antibody cetuximab was ineffective in a phase III trial in patients with locally advanced and metastatic pancreatic cancers ( Table 2) . 28 no objective responses were seen in phase II trials of cetuximab in combination with gemcitabine and intensity-modulated radiotherapy or cisplatin. 29, 30 A phase II trial of cetuximab in combination with docetaxel and irinotecan is ongoing. 31 
Gastrin-cholecystokinin B receptor pathway
The peptide hormone gastrin is secreted by G cells in the gastric antrum and duodenum, and it can act as a growth factor for gastric, colonic and pancreatic cancers. CCK-BR (the gastrin and cholecystokinin B receptor), gastrin precursors and the fully amidated gastrin are expressed in 95%, 55-91% and 23% of pancreatic cancers, respectively. 32 A selective CCK-BR antagonist, gastrazole, was tested in two small, randomized, controlled trials in patients with advanced pancreatic cancer ( Table 2) . 33 Gastrazole was superior to placebo, but not to 5-fluorouracil. Another inhibitor, the orally active Z-360, has demonstrated promising laboratory results 34 and is tolerated well by patients in combination with gemcitabine. 35 A phase III trial of Z-360 is being planned. An alternative approach to blockade of this pathway involves the use of gastrimmune, an immuno gen that stimulates the formation of anti bodies against gastrin 17 and its precursors. This agent was, however, not successful in a phase III trial (Table 2) . 36 
Angiogenesis
Angiogenesis is essential for solid tumor growth, and is principally mediated by the vEGF family of proteins and receptors ( Figure 2 ). stimuli that upregulate vEGF expression include hypoxia, other growth factors and oncogenic proteins (for example, TGF-β, EGF and Ras). vEGF is overexpressed in >90% of pancreatic cancers 37 and is, therefore, an appealing target for therapy. reviews Bevacizumab is a humanized antibody against vEGF and is approved for use in patients with colorectal cancer. However, a phase III trial in advanced pancreatic cancer failed to show any survival benefit for bevacizumab in combination with gemcitabine (Table 2) . 38 The AvITA (Bo17706) phase III study of patients with metastatic pancreatic cancer reported that the addition of bevacizumab to gemcitabine and erlotinib did not significantly prolong overall survival, although a significant improvement in progression-free survival was seen (Table 2) . 39 A number of other trials are being conducted to examine bevacizumab in combination with other agents or treatment modalities for pancreatic cancer; however, this agent seems unlikely to confer sufficient benefit to justify its licensing for this condition.
The failure of bevacizumab in therapeutic trials for pancreatic cancer highlighted the need for angiogenic inhibitors that could target other non-vEGF pathways and have better access to the tumor environment than an antibody. sorafenib is a multitargeted kinase inhibitor that inhibits the vEGF receptor (vEGFR), platelet-derived growth factor receptor (PDGFR), sCFR (formerly c-KIT), Raf1 and FlT3, which are all implicated in tumor growth and angiogenesis. sorafenib was approved in 2005 for the treatment of advanced renal-cell carcinoma. However, a phase II study concluded that, although well-tolerated, it was inactive in patients with advanced pancreatic cancer. 40 Axitinib at high concentrations is an orally active inhibitor of both vEGFR and related tyrosine kinase receptors. A median survival of 6.9 months was reported for axitinib combined with gemcitabine compared with 5.6 months for gemcitabine alone in a phase II trial in patients with advanced pancreatic cancer, but this finding was not significant. 41 Phase III trials of axitinib combined with gemcitabine are currently in progress. Aflibercept, a recombinant fusion protein that functions as a soluble decoy receptor and thereby inhibits vEGF, is another novel agent being tested in a phase III trial of patients treated with gemcitabine for metastatic pancreatic cancer.
Integrin receptors on the cell surface interact with the extracellular matrix and mediate various signaling PTeN has the opposite effect to Pi3K and inhibits the Akt pathway. Proteasomes degrade iκB, which normally inhibits NFκB. b | Binding of TGF-β forms a complex with TGFBr1 and TGFBr2, which leads to phosphorylation of sMAD2 and sMAD3. These proteins form a complex with sMAD4, which migrates to the nucleus to activate gene transcription. c | The embryonic signaling pathways. Binding of hedgehog proteins to PTC1 stops inhibition of sMO, which leads to activation of downstream targets, such as GLi1. Activation of Notch by its ligands Delta and Jagged leads to its proteolytic cleavage by γ-secretase, and releases the cytoplasmic domain, which translocates to the nucleus and binds to transcription factors, such as CsL. β-Catenin is normally destined for proteasomal degradation. in the canonical wnt-β-catenin pathway, binding of wnt proteins stabilizes β-catenin and induces its translocation to the nucleus. β-Catenin forms a complex with the TCF-LeF transcription factors to initiate gene expression. Abbreviation: CD, cytoplasmic domain. reviews pathways (Figure 2 ). These receptors are involved in many neoplastic processes, including tumor survival, invasion and metastasis. The α v β 3 and α v β 5 integrins induce angiogenesis, principally via basic fibroblast growth factor and vEGF, respectively. Cilengitide inhibits these integrins, but in a phase II trial in patients with advanced pancreatic cancer it did not show significant benefit compared to gemcitabine alone. 42 other anti-integrin agents, including an antibody against α 5 β 1 (volociximab) 43 and an inhibitor of α2 (E7820), 44 are in early-phase clinical trials.
Matrix metalloproteinases
Matrix metalloproteinases (MMPs) are a family of zincdependent proteolytic enzymes that degrade the extracellular matrix and are essential for tumor spread and neovascularization. Imbalance between MMPs and their natural inhibitors is unsurprisingly, therefore, a frequent event in pancreatic cancer. Despite promising laboratory results, MMP inhibitors have failed to live up to their initial therapeutic expectation in three phase III clinical trials (Table 2) , [45] [46] [47] although critics argued that the trials included a large number of patients with metastatic disease, which contradicts the rationale of exploiting the cytostatic effect of MMP inhibitors.
Other potential therapeutic targets

Signal-transduction pathways
The PI3K-Akt pathway upon activation by Ras or EGFR, PI3K activates Akt, which in turn has multiple downstream targets, including the mammalian target of rapamycin (mToR) and the transcription factor nFκB (Figure 2 ). mToR and nFκB have a variety of roles in cell proliferation, survival, resistance to apoptosis, angiogenesis and invasion. AKT2 is amplified and the PI3K-Akt pathway is activated in 20% and 59% of pancreatic cancers, respectively. 48, 49 Deregulation of this pathway through aberrant expression of PTEn (phosphatase and tensin homolog, a natural antagonist of PI3K) is frequently observed in pancreatic cancer. 50 Furthermore, an architectural transcription factor, HMGA-1, is overexpressed in pancreatic cancer. 51 This transcription factor activates PI3K-Akt signaling and seems to mediate resistance to gemcitabine, 52 which, therefore, provides another target for inhibition therapy. 53, 54 Temsirolimus is an mToR inhibitor approved for the treatment of renal-cell carcinoma, but use of this agent in pancreatic cancer has been limited. 55 other agents, including everolimus and sirolimus, are currently being n/a n/a a significant. Abbreviations: CALGB, Cancer and Leukemia Group B; Cr or Pr, complete or partial response; eGFr, epithelial growth factor receptor; FTi, farnesyltransferase inhibitor; MMPi, matrix metalloproteinase inhibitor; n/a, not applicable; NCiC CTG, National Cancer institute of Canada Clinical Trials Group; PFs, progression-free survival; swOG, southwest Oncology Group; veGF, vascular endothelial growth factor. reviews studied in phase II clinical trials. 56 A combination of an mToR inhibitor with other standard or targeted therapies might be needed, 57, 58 as mToR expression does not correlate with survival of patients. 59 Curcumin, which is derived from the spice turmeric, can inhibit nFκB and, therefore, the expression of regulated gene products, such as Bcl2, BclXl, CoX2, cyclin D1 and survivin, which all have a role in the survival of pancreatic cancer cells. 60, 61 Curcumin can also alter the expression of miRnAs (microRnAs, see below) in pancreatic cancer cells. 62 Phase II trials of curcumin with and without gemcitabine showed that it was welltolerated and might have some biological activity in patients with pancreatic cancer. 63, 64 The oral inhibitor of nFκB-sTAT3, RTA 402, is being examined in a phase I-II trial. Bortezomib is a proteosome inhibitor that prevents the degradation of IκBβ, which in turn is an endogenous inhibitor of nFκB (Figure 2) . Bortezomib is licensed for the treatment of refractory multiple myeloma, but unfortunately it failed to show any benefit-either alone or in combination with gemcitabine-in a phase II trial. 65 This finding could be related to the fact that proteosome inhibi tion paradoxically activates other antiapoptotic and mitogenic sig naling pathways in pancreatic cancer. 66 The cyclo-oxygenase pathway The CoX enzymes have principal roles in the conversion of arachidonic acid into prostaglandins. CoX1 is constitutively expressed and has a homeostatic role. CoX2 is inducible by growth factors, cytokines and tumor promoters, and its expression is upregulated in 90% of pancre atic cancers. 67 The mechanisms of CoX-mediated and prostaglandin-mediated pancreatic cancer development are complex; they involve multiple mitogenic signaling pathways and molecules that mediate resistance to apoptosis, cell migration, invasion, angiogenesis, immuno suppression, the production of free radicals and peroxidation of pro carcinogens to carcinogens. 68 Inhibition of CoX2 by nsAIDs has suppressed proliferation of pancre atic cancer cells and angiogenesis, both in vitro and in vivo. 68, 69 Interestingly, Chang and colleagues reported in 2008 that the antitumor activity of celecoxib does not correlate with its inhibition of CoX2, which suggests the involvement of alternative mechanisms. 70 nonetheless, phase II trials of gemcitabine in combination with celecoxib 400 mg twice daily have been conducted, but results were inconclusive. For 20 evaluable patients with metastatic pancreatic cancer, the reported median survival was 6.2 months and survival at 3 months was 72%. 71 For patients with locally advanced or metastatic disease, one study showed an median survival of 9.1 months and overall clinical response of 54.7%, 72 but another study concluded that the addition of celecoxib had no significant benefit. 73 The combination of celecoxib, gemcitabine and irino tecan resulted in a median survival of 13 months and 1-year survival of 64%, and was associ ated with improvement of pain and quality of life. 74 A phase III trial of gemcitabine, celecoxib and curcumin is in progress.
The TGF-β-SMAD4 pathway TGF-β is a cytokine secreted by epithelial, endo thelial, hematopoietic and mesenchymal cells. Binding of TGF-β forms a heteromeric complex with the type I and type II TGFBR triggers the phosphorylation of cytoplasmic sMAD2 and sMAD3. In turn, these sMAD proteins form a complex with sMAD4, which translocates into the nucleus to activate gene transcription (Figure 2) . TGF-β can also signal via sMAD-independent pathways that involve Ras, PI3K and MAPK. TGF-β mediates a wide range of physiological processes, such as embryonic development, tissue repair, angiogenesis and immunosuppression. TGF-β also has a complex role in tumorigenesis, as it is tumor-suppressive in epithelial cells, but promotes invasion and meta stasis during the late stages of cancer progression. Mutations of the TGFBR1, TGFBR2 and SMAD4 genes are found in about 1%, 4% and 50% of patients with pancreatic cancers, respectively. 75 Inactivation of sMAD4 abolishes TGF-β-mediated tumor-suppressive functions while it maintains some tumor-promoting TGF-β responses, such as epithelial-mesenchymal transition, which makes cells migratory and invasive. 76 TGF-β-based therapeutic strategies are currently in development, including inhibitors of TGFBR1 and TGFBR2. 77, 78 AP 12009, an antisense oligonucleotide specific to TGF-β2, is currently being tested in a phase I-II study of malignant melanoma, pancreatic cancer and colorectal carcinomas. one patient with advanced pancre atic cancer was still alive 128 weeks after complete regression of liver metastases. 79 The hepatocyte growth factor receptor pathway The MET oncogene encodes the receptor for hepatocyte growth factor (HGF) and is overexpressed in 78% of pancreatic cancers. 80 HGF is normally produced by mesenchymal cells and acts on epithelial cells to promote tissue regeneration. In hypoxic conditions, however, tumor-associated fibroblasts produce HGF, which stimulates angiogenesis, tumor growth, cell motility and extracellular matrix breakdown and leads to invasion and metastasis (Figure 2 ). Targeting the HGF pathway with use of a synthetic competitive antagonist of HGF 81, 82 and an antibody against the MET receptor 83 has yielded encouraging results in the laboratory setting. ARQ 197 is a MET receptor tyrosine kinase inhibitor that is currently being tested in a phase II trial. A phase I study showed that it was tolerated well by patients. 84 The insulin-like growth factor pathway The insulin-like growth factor I (IGF-I) receptor, a transmembrane receptor tyrosine kinase, is overexpressed in 64% of pancreatic cancers. 85 The IGF-I receptor has antiapoptotic and growth-promoting effects and acts via multiple signaling cascades, including the PI3K-Akt, MAPK and sTAT pathways (Figure 2) . Inhibition of the IGF-I receptor by the tyrosine kinase inhibitor nvP-AEW541, a dominant-negative mutant and RnA interference have reviews all been shown to reduce the growth of pancreatic cancer cells in vitro and in vivo, and increase chemotherapyinduced or radiation-induced apop tosis. 86, 87 Concomitant inhibition of KRas increases the thera peutic effect of this inhibitor. 88 Human anti-IGF-I receptor antibodies have been reported to increase the antitumor effects of gemcitabine and EGFR inhibition in vivo. 89, 90 As a result of these findings, phase I-II trials of cixutumumab and MK-0646 with gemcitabine and erlotinib have now commenced for pancreatic cancer.
The focal adhesion kinase pathway
Focal adhesion kinase (FADK) is a cytoplasmic nonreceptor tyrosine kinase that mediates functions involved in cell motility and survival and is closely related to the integrin signaling pathway (Figure 2) . 48% of pan creatic cancers 91 express FADK and, importantly, it shares a common pathway with IGF-I receptor. 92 The dual IGF-I receptor-FADK inhibitor nvP-TAE226 has shown signifi cant tumor-suppressive activity in vivo. 93 The Src pathway src is one of nine members of the src family of nonreceptor protein tyrosine kinases. In normal conditions, src is maintained in a phosphorylated and inactive form, but is activated in a number of malignancies, including in 70% of pancreatic cancers. 85 src has diverse roles in cell proliferation, survival, motility, invasiveness, resistance to chemotherapy and angiogenesis. This protein acts via multiple signaling pathways and, therefore, is an ideal target for therapeutic intervention (Figure 2 ). src kinase inhibitors have been effective in suppressing pancreatic tumor growth and metastasis in vivo. [94] [95] [96] Dasatinib is an orally active multitargeted kinase inhibitor of src, BCRABl, PDGFR, ephrin type A receptor 2 and sCFR, and is licensed for the treatment of chronic myelogenous and acute lymphoblastic leukemias. Dasatinib is being examined in a phase II trial in patients with metastatic pancreatic cancer, as is the related compound saracatinib.
embryonic signaling pathways
The hedgehog pathway Three mammalian hedgehog homolog proteins have been identified-DHH, IHH and sHH. These proteins are secreted and specify the organization and structure of many tissues during embryonic development. Activation of the hedgehog signaling pathway is controlled by two transmembrane proteins, the tumor-suppressor PTC1 protein and the oncogenic sMo protein (Figure 2 ). PTC1 normally suppresses sMo, but mechanisms, such as an inactivating mutation of PTC1 and the binding of hedgehog proteins to PTC1, relieves this inhibition, which leads to sMo activation of transcriptional responses. sHH is expressed in 70% of human pancreatic adeno carcinomas. 97 IHH expression is increased 35-fold in pancreatic cancer cells compared with in normal tissues. 98 Mechanisms of tumorigenesis include the effects of hedgehog proteins on the cell-cycle regulators, protection from apoptosis via PI3K-Akt signaling and stabilization of Bcl2 and BclXl and collaboration with activated KRas and angio genesis. The hedgehog signaling pathway can be inhibited by cyclopamine, which binds to sMo. laboratory work has demonstrated the effectiveness of cyclopamine in a wide range of digestive-tract tumors, including pancre atic cancer. 99 Cyclopamine can enhance sensitivity to radiotherapy and chemotherapy and suppress metastatic spread 100, 101 as well as improving anti tumor activity when combined with an EGFR inhibitor. 102 A downstream target of the sHH pathway, the trans cription factor GlI1, can also be inhibited by miRnA. 103 The Notch pathway The four known human notch genes encode heterodimeric transmembrane receptors, which are important in the development of organs, tissue proliferation, differentiation and apoptosis. Activation of the notch signaling pathway leads to proteolytic cleavage of the trans membrane receptors by γ-secretase; the released cytoplasmic domain then migrates to the nucleus and binds to transcription factors, which leads to the expression of a variety of genes ( Figure 2 ). notch signaling occurs downstream of Ras, EGFR and TGF-β signaling in pancreatic tumorigenesis and promotes tumor vasculariza tion. Downregulation of notch 1 with siRnA or curcumin (owing to the crosstalk between notch and nFκB signaling pathways) can inhibit cell growth and induce apoptosis in pancreatic cancer cell lines in vitro.
104,105 notch 3 is expressed in around 70% of pancreatic cancers and can be inhibited by siRnA and γ-secretase inhibitors (GsI and l-685,458).
106,107
The Wnt pathway 19 human Wnt genes each encode a lipid-modified secreted glycoprotein. Wnt signaling is involved in normal embryonic development and homeostatic self-renewal of a number of adult tissues. There are three Wnt signaling cascades, namely the canonical Wnt-β-catenin, the planar-cell polarity, and the Wnt-Ca 2+ pathways. The former is the best known and has been implicated in a variety of cancers, including liver, colo rectal, breast, prostate, renal and hematological malignancies. normally, β-catenin is phosphorylated and targeted for degradation. However, binding of Wnt proteins results in activa tion of intracellular pathways that cause β-catenin to enter the nucleus, where its inter action with the T-cell factor and lymphoid enhancer factor families of transcription factors leads to targeted gene expression (Figure 2) . Any gain-offunction mutation of activators or loss-of-function mutation of inhibitors of Wnt signaling could lead to aberrant activa tion of these signaling pathways, which could result in carcino genesis and progression. Aberrant activation occurs in 65% of pancreatic cancers. 108 Inhibition of Wnt signaling to reduce prolifera tion and increase apoptosis of pancreatic cancer cells has been achieved in the laboratory setting by a variety of methods, including the use reviews of β-catenin-interacting protein 1, a dominant-negative mutant of lymphoid enhancer factor, and siRnA against β-catenin or extracellular sulfatases. 109, 110 Wnt signaling is positively regulated by the hedgehog and sMAD4 sig naling pathways, 109, 111 which could be targets for a combined inhibitory therapeutic strategy.
The CXC-chemokine receptor 4 (CXCR 4) and its ligand, sDF-1 have a role in tumor growth, angiogenesis and, in particular, metastatic spread. In vitro blockade of CXCR 4 could inhibit pancreatic cancer growth through inhibition of the canonical Wnt pathway. 112 Furthermore, plerixafor, an antagonist of CXCR 4, reduces metastasis by pancreatic cancer cells that are positive for the markers CXCR 4 and CD133 (the latter is a marker of pancreatic cancer stem cells) in vivo.
telomerase
The telomeres located at the end of chromosomes normally shrink with each cell division and thereby impose a finite lifespan on the cell. Most malignant cells have detectable activity of telemerase, a reverse transcriptase that contains an RnA template and acts to elongate telomeres. Telomerase is overexpressed in 95% of pancreatic cancers 114 which provides a rationale for the development of antitelomerase agents. Gv1001 is a telomerase peptide vaccine that has shown some promising results in phase I/II studies. 115, 116 This vaccine is being tested in the large (>1,000 patients), phase III, Telovac trial with gemcitabine and capecitabine in locally advanced and metastatic pancreatic cancers.
MicroRNAs
The miRnAs are small, endogenous, noncoding RnA molecules that regulate gene expression and are important for developmental and physiological processes. These molecules all negatively regulate gene expression post-transcriptionally and can be either oncogenic or tumor-suppressive, depending on their target mRnAs. 117 Expression profiling showed that at least 100 miRnA precursors are aberrantly expressed in pancreatic cancer or desmoplasia. 118, 119 Anticancer miRnA-based therapy has the theoretical advantage of having multiple targets that are controlled by an individual miRnA by virtue of its post-transcriptional modulation. Therapeutic strategies include the reconstitution of tumor-suppressive miRnAs and the knockdown of oncogenic miRnAs by coding vectors or anti-miRnA oligonucleotides. studies of these treatment approaches have been limited in pancreatic cancer but have yielded promising results in breast cancer and glioma.
Cancer stem cells
Cancer stem cells possess important properties associated with their normal counterparts, namely the ability for self-renewal and differentiation. Pancreatic cancer stem cells are identified by their surface markers, such as CD133, CD44, CD24 and flotillin 2 epithelial-specific antigen. Evidence suggests that such cells form a small subset in the heterogenous tumor population, and contribute to neoplastic progression, metastasis and resistance to chemotherapy and radiotherapy. 113, 120 For this reason, cancer stem cells are thought to be responsible for relapse of disease after clinical remission. Dysregulation of various signaling cascades, including the PTEn, sHH, notch and Wnt pathways, are frequently observed in cancer stem cells, which provides further rationale for use of these pathways as a target for therapeutic purposes. Further studies are still needed to understand the genetic and biological properties of cancer stem cells for the development of effective treatment modalities.
Conclusions
Although targeted therapies for pancreatic cancer have yielded encouraging results in vitro and in animal models, these findings have not been translated to improved outcomes in clinical trials. Reasons for this failure might include an incomplete understanding of the biology of pancreatic cancer, the selection of poor active agents, problems with trial design (such as inappro priate therapeutic end points or patient selection) and the rapidity with which agents move into randomized, controlled trials without the extensive early testing neces sary to optimize treatment regimens. Furthermore, pre clinical studies performed on mouse models do not always recapitulate the human condition, which is a particular problem with human pancreatic cancer xenografts in immunodeficient mice. Despite these setbacks, lessons have been learnt, and our collective effort has generated a substantial platform of knowledge from which further work could spring. Genetically engineered immunocompetent mice, such as those with KRAS or TP53 mutations, have been developed and they hold promise for the future studies of the disease. 121 The bio availability of compounds such as antisense oligo nucleotides and siRnAs in humans remains a big hurdle, which will require further improvement of gene-delivery strategies. The individualization of therapy for patients is possible if factors that predict treatment response, such as biological markers, could be determined accurately. Alternatively, resected tumors could be grown in laboratory mice and treated with a series of drugs, and the most effective agent subsequently administered to the patient. This concept is currently being tested in a phase II trial at Johns Hopkins Hospital, MD, us. until this strategy is proven effective in the clinical setting, multimodal approaches will remain the mainstay of treatment for advanced pancreatic cancer. These approaches are likely to comprise a mixture of targeted agents in combination with conventional chemotherapy and radiotherapy. For a clinically relevant effect to be achieved, treatment strategies should either be in the form of a 'horizontal' approach, in which several oncogenic pathways are inhibited, or a 'vertical' approach, whereby multiple levels of a major pathway are targeted. one example currently being investigated in a phase III trial is the treatment combination of celecoxib, curcumin and gemcitabine for advanced pancreatic cancer. Besides the synergistic antiproliferative and proapoptotic effects of curcumin and celecoxib, 122 these agents also potentiate the anti tumor activity of gemcitabine. 123, 124 Combination therapies, together with improved diagnostic tools and predictive markers, are ultimately hoped to improve the bleak outlook for patients diagnosed with pancreatic cancer. For now, the results of a number of phase III trials are eagerly awaited (Table 3) .
Review criteria
PubMed was searched in November 2008 for english-language publications, using the terms "pancreatic", "pancreas", "carcinoma", "cancer", "therapy", "treatment" and those listed in the articles' subheadings. Published reports and abstracts from the American society of Clinical Oncology and the American Association for Cancer research meetings, were also searched. No exclusion criteria were used. Articles were selected on the basis of relevance and additional papers were identified from their reference lists. The National Cancer institute website was searched for ongoing clinical trials.
